3-(2-methyl-pyrrolidino)-propan-1-ol | 133208-52-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(2-methyl-pyrrolidino)-propan-1-ol
• 英文别名: 3-(2-methyl-1-pyrrolidinyl)-1-propanol；3-(2-methylpyrrolidin-1-yl)propan-1-ol
• CAS: 133208-52-3
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: SFAXHRYTDJJHII-UHFFFAOYSA-N

物化性质

• 沸点：
  100 °C(Press: 18 Torr)
• 密度：
  0.9384 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-methyl-pyrrolidino)-propan-1-ol 、 2,6-dimethyl-4-propoxy-benzoyl chloride 生成 2,6-dimethyl-4-propoxy-benzoic acid-[3-(2-methyl-pyrrolidino)-propyl ester]
  参考文献：
  名称：

  Pyrrolidyl-alkyl esters of 2, 6-dimethyl-4-propoxybenzoic acids

  摘要：

  公开号：

  US02719851A1
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 3-(2-methyl-pyrrolidino)-propan-1-ol
  参考文献：
  名称：

  PYRROLIDYL ALKANOLS

  摘要：

  DOI：

  10.1021/jo01157a020

文献信息

• Pyridizinone derivatives
  申请人：Hudkins L. Robert

  公开号：US20080027041A1

  公开（公告）日：2008-01-31

  The present invention provides compounds of formula (I*): their use as H 3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.

  本发明提供了式(I*)的化合物：它们作为H3抑制剂的用途，其制备方法以及药物组合物。
• COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
  申请人：XW LABORATORIES INC.

  公开号：US20200102289A1

  公开（公告）日：2020-04-02

  The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.

  本发明涉及作为H3R拮抗剂的化合物(A)的公式，以及它们的制备和用途，并进一步涉及包含这些化合物的药物组合物及其用途作为组胺3受体（H3R）功能调节剂。本发明还涉及这些化合物或药物组合物在治疗或预防与人类H3R功能相关的某些疾病和疾病中的用途。
• Phenyl-oxazoles, a New Family of Inverse Agonists at the H₃Histamine Receptor
  作者：Frédéric Denonne、Franck Atienzar、Sylvain Célanire、Bernard Christophe、Frédérique Delannois、Christel Delaunoy、Marie-Laure Delporte、Véronique Durieu、Michel Gillard、Bénédicte Lallemand、Yves Lamberty、Geneviève Lorent、Alain Vanbellinghen、Nathalie Van houtvin、Valérie Verbois、Laurent Provins

  DOI：10.1002/cmdc.200900446

  日期：2010.2.1

  Drug design: Oxazoles and thiazoles were designed and synthesised based on previously reported ligands of the 3rd histamine receptor (H3R). The aminopropoxy‐phenyl‐oxazole chemotype was identified as a promising H3R inverse agonist with superior drug‐like properties, good efficacy in vivo and good safety margin.

  药物设计：恶唑和噻唑是基于先前报道的第三组胺受体（H 3 R）的配体设计和合成的。氨基丙氧基-苯基-恶唑的化学型被认为是一种有前途的H 3 R反向激动剂，具有出色的类药物特性，体内良好的疗效和良好的安全性。
• Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses
  申请人：Celanire Sylvain

  公开号：US20090023708A1

  公开（公告）日：2009-01-22

  The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals.

  本发明涉及公式（I）的化合物，包括内酰胺或内酰胺衍生物基团，制备它们的过程，包括所述化合物的制药组合物以及它们作为药物的用途。
• Substituted Pyridone Derivative
  申请人：Ohtake Norikazu

  公开号：US20080269287A1

  公开（公告）日：2008-10-30

  Compounds of a formula (I) [wherein, A represents formula (III-1) R3 is a hydrogen, lower alkyl et al; m is 0 or 1; R1 is a hydrogen atom, halogen atom et al, R2 is a hydrogen et al; p is 0 to 4; X is a carbon atom or nitrogen atom; and X1 to X4 is a lower alkyl et al], or pharmaceutical acceptable salts thereof. These have a potency antagonistic to binding to histamine H3 receptor, or have a potency inhibiting the constant activity of histamine H3 receptor, and are useful in the therapy of obesity, diabetes et al.

  公式（I）的化合物[其中，A代表公式（III-1），R3是氢，低碳基等; m为0或1; R1是氢原子，卤原子等，R2是氢等; p为0到4; X是碳原子或氮原子; X1到X4是低碳基等]，或其药学上可接受的盐。这些化合物具有对组胺H3受体的拮抗作用，或具有抑制组胺H3受体的恒定活性的功效，并可用于肥胖症、糖尿病等疾病的治疗。